Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2013

View Archived Issues

Frontotemporal dementia model reveals activity of PPAR agonist

Researchers from Germany develop novel marmoset model of MS

[18F]-MNI-659 striatal binding significantly correlates with HD severity

SK Biopharmaceuticals forms drug development alliance with Chinese companies

BMN-165 treatment leads to early Phe reductions in adults with PKU

Researchers discover LXR inverse agonist for the potential treatment of nonalcoholic hepatosteatosis

FYU-981 shows potential as a novel therapy for hyperuricemia

FDA approves Quartette for the prevention of pregnancy

ArQule regains rights to ARQ-092

Axelar reports preliminary data from phase II study of AXL-1717

Novel SSAO inhibitors prepared at Proximagen

French group isolates novel anticancer compound from Guiera senegalensis

Fovea Pharmaceuticals divulges prostanoid EP2 receptor agonists

Radboud Universiteit Nijmegen develop exon skipping molecules for Leber's congenital amaurosis

BioMarin submits Vimizim BLA to FDA

BioCryst Pharmaceuticals provides regulatory update on peramivir

NeoStem receives second year of grant for very small embryonic-like stem cells

Alimera resubmits Iluvien NDA for chronic diabetic macular edema

Reva Medical begins ReZolve2 trial

Stribild combination tablets approved in Japan

FDA issues complete response letter for APF-530

GSK applies for approval in Japan of new Votrient indication

Istradefylline approved in Japan for Parkinson's disease

Neoral receives an additional indication approval in Japan

Clavis Pharma suspends development of elacytarabine